Quantcast

Latest Antiretroviral drug Stories

2014-05-28 23:15:08

Professor Mark Wainberg from McGill University in Montreal shows that Dolutegravir rarely selects for resistance mutations and when they occur, HIV growth is impaired. Toulon, Var, France (PRWEB) May 28, 2014 Professor Mark Wainberg stated at the ISHEID that "Dolutegravir resistance is very difficult to obtain in vitro" and that this situation is unique among other antiretrovirals. A New Mechanism of Resistance Selection Actually, Dolutegravir is the last approved integrase...

2014-05-21 12:16:10

IQWiG Added benefit based on fewer side effects / no data for adolescents and pretreated adults who do not require integrase inhibitors Dolutegravir has been approved since January 2014 in combination with other antiretroviral drugs for the treatment of human immunodeficiency virus (HIV) infected adults and adolescents above 12 years of age. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG), the German Institute for Quality...

2014-05-19 09:55:53

University of Pittsburgh Schools of the Health Sciences The first direct proof of a long-suspected cause of multiple HIV-related health complications was recently obtained by a team led by the University of Pittsburgh Center for Vaccine Research (CVR). The finding supports complementary therapies to antiretroviral drugs to significantly slow HIV progression. The study, which will be published in the June issue of the Journal of Clinical Investigation and is available online, found that...

2014-05-16 23:05:57

The CDC’s Guidelines Expand the Pool of Patients Who Should Be Educated About PrEP Boston, MA (PRWEB) May 16, 2014 Fenway Health and The Fenway Institute strongly support the May 14 recommendations issued by the United States Centers for Disease Control and Prevention on the use of pre-exposure prophylaxis (PrEP) for HIV prevention. PrEP is a proven tool for preventing HIV infection, reducing chances of infection by up to 92% according to several studies, including the iPrex study that...

Researcher Finds Soy Sauce Molecule May Unlock Drug Therapy For HIV Patients
2014-05-05 03:45:36

Jeff Sossamon / Roger Meissen, University of Missouri Compounds can be 70 times more potent than Tenofovir, a first-line HIV regimen For HIV patients being treated with anti-AIDS medications, resistance to drug therapy regimens is commonplace. Often, patients develop resistance to first-line drug therapies, such as Tenofovir, and are forced to adopt more potent medications. Virologists at the University of Missouri now are testing the next generation of medications that stop HIV from...

2014-05-02 10:06:07

Enzyme's double-edged sword may soon be sheathed Johns Hopkins biochemists have figured out what is needed to activate and sustain the virus-fighting activity of an enzyme found in CD4+ T cells, the human immune cells infected by HIV. The discovery could launch a more effective strategy for preventing the spread of HIV in the body with drugs targeting this enzyme, they say. A summary of their work was published online on April 21 in the journal Proceedings of the National Academy of...

2014-05-01 20:24:08

HealthHIV's Third Annual State of HIV Primary Care National Survey Identifies Significant Training Needs and Barriers to Quality Care WASHINGTON, May 1, 2014 /PRNewswire-USNewswire/ -- Primary care providers who provide clinical HIV care (HIV PCPs) are experiencing rising HIV caseloads from newly insured patients under the Patient Protection and Affordable Care Act (PPACA), according to a national survey released today by HealthHIV. Forty percent of those surveyed say that the number of...

2014-04-30 11:01:45

The risks of birth defects in children exposed to antiretroviral drugs in utero are small when considering the clear benefit of preventing mother-to-child transmission of HIV but where there are safe and effective alternatives, it might be appropriate to avoid use by pregnant women of drugs that may be associated with elevated risks of birth defects, such as zidovudine and efavirenz, according to a study published by French researchers published in this week's PLOS Medicine. The...

2014-04-30 09:35:16

People infected with HIV whose immune cells have low cholesterol levels experience much slower disease progression, even without medication, according to University of Pittsburgh Graduate School of Public Health research that could lead to new strategies to control infection. The Pitt Public Health researchers found that low cholesterol in certain cells, which is likely an inherited trait, affects the ability of the body to transmit the virus to other cells. The discovery, funded by the...

2014-04-26 12:20:58

DALLAS, April 26, 2014 /PRNewswire/ -- RnRMarketResearch.com offers Pancreatic Adenocarcinoma Therapeutics in Major Developed Markets to 2019 - Early Stage Pipeline Shows Diversity of Novel Targets though Commercial Impact Remains Distant and HIV Therapeutics in Major Developed Markets to 2019 - Limited Pipeline Efficacy Improvement, Patent Expirations and Stringent Healthcare Spending to Suppress Market Growth research reports in its store. Human Immunodeficiency Virus...


Latest Antiretroviral drug Reference Libraries

0_a4499f7c8759b5cbe79bad5eca319070
2011-01-26 14:08:59

Human immunodeficiency virus (HIV), a lentivirus, causes acquired immunodeficiency syndrome (AIDS) which is a condition in humans were the immune system begins to fail, leading to life-threatening opportunistic infections. Infection is transferred through bodily fluids where HIV is present as both free virus particles and within infected immune cells. The four most common routes of infection are unsafe sex, contaminated needles, breast milk, and transmission from an infected mother to her...

More Articles (1 articles) »
Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.